Evidence map›Paper›PMID 37930485›Full record

ArticleJournal of materials science. Materials in medicine2023

Development of in situ crosslinked hyaluronan as an adjunct to vitrectomy surgery.

Kiyoshi Suzuki, Ippei Watanabe, Takashi Tachibana, Kenichiro Mori, Keijiro Ishikawa, Tatsuro Ishibashi, Eiichi Uchio, Koh-Hei Sonoda, Toshio Hisatomi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials science. Materials in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Silicone oil tamponade in vitreoretinal surgery and future perspective: a narrative review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kiyoshi SuzukiCentral Research Laboratories, Seikagaku Corporation, 1253, Tateno 3-chome, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Ippei WatanabeCentral Research Laboratories, Seikagaku Corporation, 1253, Tateno 3-chome, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Takashi TachibanaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kenichiro MoriDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Keijiro IshikawaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Tatsuro IshibashiDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Eiichi UchioDepartment of Ophthalmology, Faculty of Medicine, Fukuoka University, 8-19-1, Nanakuma, Fukuoka Jonan-ku, Fukuoka, 814-080, Japan.
Koh-Hei SonodaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Toshio HisatomiDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. t.hisatomi.qk@fukuoka-u.ac.jp.ORCID http://orcid.org/0000-0003-2552-9595

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ophthalmologists have used hyaluronan (HA) products as adjuncts to ocular surgery since the 1970s. However, HA products are not always functional in surgeries of the posterior eye segment due to their lack of biomechanical strength. In this study, we developed an in situ crosslinked HA (XL-HA) and evaluated its potential as an adjunct to vitrectomy surgery in an in vitro model with a triamcinolone acetonide (TA) layer used as a pseudo residual vitreous cortex (RVC). Within a few minutes at concentrations over 0.9%, XL-HA, generated by the click chemistry of HA-dibenzocyclooctyne and HA-azidoethylamine, formed a hydrogel with the appropriate hardness for tweezers peeling. XL-HA (concentration, 0.76-1.73%) without dispersion successfully entered the TA layer and removed more than 45% of the total TA. Dynamic viscoelasticity helps to explain the rheological behavior of hydrogels, and the assessment results for XL-HA indicated that suitable concentrations were between 0.97% and 1.30%. For example, 1.30% XL-HA hydrogel reached sufficient hardness at 3 min for tweezers peeling, and the TA removal ability exceeded 70%. These results demonstrated that XL-HA was a potential adjunct to successful vitrectomy.

Indexed as

Hyaluronic AcidOphthalmologyHardnessHydrogelsVitrectomyHyaluronic AcidHydrogelsIn situ crosslinked hyaluronanOphthalmic viscoelastic deviceRemovalResidual vitreous cortexVitrectomy

Identifiers

PMID37930485
PMCPMC10628021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.